Investment
Features
FeesSafety
Academy
More
Pluang+

Compare F5 Inc (FFIV) vs Heron Therapeutics Inc (HRTX) Price & Performance

Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

F5 Inc vs Heron Therapeutics Inc — how do they compare? F5 Inc trades at $421.38 (market cap $23.44B), while Heron Therapeutics Inc trades at $0.33 (market cap $61.47M). The key difference: F5 Inc is far larger — about 381.3× Heron Therapeutics Inc's market cap, and F5 Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

FFIVHRTX
Market Cap
$23.44B$61.47M
Sector
TechnologyHealth
52-Week High
$431.26$1.49
52-Week Low
$223.99$0.32
Enterprise Value
$22.08B$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

F5 Inc

F5 (FFIV) trades at $414.00, up 0.98% in the last session, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $3.09 billion in 2025, with a net income margin of 21.95%, while the company raised its annual revenue forecast on robust cybersecurity demand (Reuters, 2026-07-27). The stock is near resistance at $417, with RSI indicating mild overbought conditions.

The outlook remains positive due to consistent earnings outperformance and AI-driven security growth, but risks include high valuation multiples (P/E of 32.98) and competitive pressures. Analysts maintain a moderate buy consensus with a $430.43 price target, suggesting potential upside from current levels.

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About F5 Inc

F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.

Read more on FFIV

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX